TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1741708

Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 6111672

Group type: EXPERIMENTAL
Intervention: Prostacyclin administration
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (no prostacyclin)
Number of subjects: 23
Study: 31036397

Group type: EXPERIMENTAL
Intervention: Everolimus eluting stents (EES)
Number of subjects: 1821

Group type: COMPARATOR
Intervention: Thin-strut paclitaxel eluting stents (PES)
Number of subjects: 1821

Group type: EXPERIMENTAL
Intervention: Stent related events (TV-MI, TVR, TLR and stent thrombosis)
Number of subjects: 1821
Study: 28651589

Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) delivered by trained mental health nurses, consisting of 8 weekly 30-minute sessions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) in primary care.
Number of subjects: 0
Study: 25455796

Group type: EXPERIMENTAL
Intervention: Website with tailored information and question prompt (QP)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 197
Study: 23934877

Group type: EXPERIMENTAL
Intervention: Group hearing aid fitting visits
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Group hearing aid follow-up visits
Number of subjects: 644

Group type: COMPARATOR
Intervention: Individual hearing aid fitting visits
Number of subjects: 644

Group type: COMPARATOR
Intervention: Individual hearing aid follow-up visits
Number of subjects: 644
Study: 21646576

Group type: EXPERIMENTAL
Intervention: Usual care plus group cognitive behavioral therapy (16 sessions of 2 hours each)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 299
Study: 19654947

Group type: EXPERIMENTAL
Intervention: Tubular retractor assisted foraminotomy/discectomy (TAF/TAFD)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Open foraminotomy/discectomy (OF/OFD)
Number of subjects: 41
Study: 16995862

Group type: EXPERIMENTAL
Intervention: Beclometasone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mometasone
Number of subjects: 30
Study: 15528912

Group type: EXPERIMENTAL
Intervention: Toothpaste fluoridation (SnF2/Olaflur; 0.14% F‐) for 3 x 5 min daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intensive fluoridation (Toothpaste + Mouthrinse (SnF2/Olaflur; 0.025% F‐) for 3 x 5 min daily + Gel (NaF/Olaflur, 1.25% F‐) on days 1 and 3)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no fluoridation)
Number of subjects: 10
Study: 12019102

Group type: EXPERIMENTAL
Intervention: Topical 5% acyclovir-1% hydrocortisone cream (ME-609)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Vehicle control (placebo)
Number of subjects: 380
Study: 9715184

Group type: EXPERIMENTAL
Intervention: Partial liquid ventilation (PLV)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 16
Study: 7494183

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium controlled-release matrix tablets (various formulations)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High viscosity grade HPMC
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Stability testing of diclofenac sodium formulations
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: In-vivo study of sustained release formulations
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: In-vitro/in-vivo correlations
Number of subjects: 6
Study: 2483977

Group type: EXPERIMENTAL
Intervention: Intrapleural BCG according to McKneally's technique (73 patients)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Levamisole (43 patients)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Isoprinosine (60 patients)
Number of subjects: 344
Study: 329860

Group type: EXPERIMENTAL
Intervention: Debendox with 10mg of extra pyridoxine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo with 10mg of pyridoxine
Number of subjects: 56
Study: 6817772

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) ointment
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 7
Study: 31157964

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 1125

Group type: COMPARATOR
Intervention: Standard care (nonsteroidal antiandrogen therapy)
Number of subjects: 1125
Study: 28201730

Group type: EXPERIMENTAL
Intervention: PRISM system
Number of subjects: 300

Group type: COMPARATOR
Intervention: Binder condition (control)
Number of subjects: 300
Study: 26628415

Group type: COMPARATOR
Intervention: Prolonged sitting (7.5 h)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Standing (5 min every 30 min)
Number of subjects: 22
Study: 25296687

Group type: EXPERIMENTAL
Intervention: Financial incentives for breastfeeding
Number of subjects: 53
Study: 22392179

Group type: EXPERIMENTAL
Intervention: Zinc (10 mg for 2‐ to 11‐month‐olds and 20 mg for older children)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study: 20729009

Group type: EXPERIMENTAL
Intervention: Left anodal/right cathodal tDCS of DLPFC (n=8)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Right anodal/left cathodal tDCS of DLPFC (n=9)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham stimulation (n=8)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Right anodal/left cathodal tDCS of DLPFC
Number of subjects: 25
Study: 17672261

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide cement (Dycal)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Acetone‐based total‐etch adhesive (Prime&Bond NT)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Non‐rinse conditioner (NRC) and Prime&Bond NT
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Total‐etching with 36% phosphoric acid followed by Prime&Bond NT
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Self‐etch adhesive system (Xeno III)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Overall success rate of direct pulp capping
Number of subjects: 67
Study: 16248452

Group type: EXPERIMENTAL
Intervention: Four skinfold protocols
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Three girth measurement protocols
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Two bioelectric impedance analysis (BIA) instruments
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: One near-infrared instrument
Number of subjects: 121

Group type: COMPARATOR
Intervention: General comparison to underwater weighing (UWW)
Number of subjects: 121
Study: 11916282

Group type: EXPERIMENTAL
Intervention: Methimazole (30 mg initial dose for at least 2 months, stopped 6 days before treatment)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Beta-blocker (atenolol 50-100 mg/d)
Number of subjects: 42
Study: 10023503

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 14
Study: 8522632

Group type: EXPERIMENTAL
Intervention: Phenytoin 200 mg and 300 mg once daily for 14 weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 2401129

Group type: EXPERIMENTAL
Intervention: Diltiazem sustained-release formulation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 49
Study: 447112

Group type: EXPERIMENTAL
Intervention: Rowachol (2 capsules, three times a day for 48 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rowachol (1 capsule, three times a day for 48 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rowachol (4 capsules, four times a day for 48 hours)
Number of subjects: 0
Study: 31553377

Group type: EXPERIMENTAL
Intervention: Lian gong group (n = 11)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation group (n = 11)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 36
Study: 28232346

Group type: EXPERIMENTAL
Intervention: NHS Health Check intervention
Number of subjects: 0
Study: 25967575

Group type: EXPERIMENTAL
Intervention: Symptomatic patients
Number of subjects: 34

Group type: COMPARATOR
Intervention: Asymptomatic patients
Number of subjects: 34
Study: 24256450

Group type: EXPERIMENTAL
Intervention: Paracetamol + placebo diclofenac
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Diclofenac + placebo paracetamol
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Paracetamol + diclofenac
Number of subjects: 547
Study: 21323785

Group type: EXPERIMENTAL
Intervention: 5% hydrogen peroxide with composite resin
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 5% sodium hypochlorite with composite resin
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Combination of 5% hydrogen peroxide and sodium hypochlorite with composite resin
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 15% EDTA with composite resin
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 10% lactic acid with composite resin
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 20% lactic acid with composite resin
Number of subjects: 140

Group type: COMPARATOR
Intervention: No irrigant (control) with composite resin
Number of subjects: 140
Study: 19674165

Group type: EXPERIMENTAL
Intervention: Dutasteride once daily for 52 weeks
Number of subjects: 378

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study: 16930852

Group type: EXPERIMENTAL
Intervention: D,L‐fenfluramine (FEN) 60 mg oral after a 7‐day cocaine‐free period
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cocaine (96 mg intranasal)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (4 mg cocaine)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Second FEN challenge
Number of subjects: 8
Study: 15577414

Group type: EXPERIMENTAL
Intervention: 5% lidocaine gel
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo gel (vehicle)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 5% lidocaine gel with neurotoxin exposure
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 5% lidocaine gel without neurotoxin exposure
Number of subjects: 64
Study: 11369252

Group type: EXPERIMENTAL
Intervention: Cisplatin-based front-line intraperitoneal therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (not specified)
Number of subjects: 0
Study: 9534319

Group type: EXPERIMENTAL
Intervention: Calcium heparin 12,500 IU twice daily for 3 months
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Calcium heparin treatment
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 204
Study: 8214753

Group type: EXPERIMENTAL
Intervention: Neostigmine (0.005, 0.01, 0.02, or 0.05 mg/kg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Edrophonium (0.1, 0.2, 0.4, or 1 mg/kg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Edrophonium
Number of subjects: 64
Study: 3122278

Group type: EXPERIMENTAL
Intervention: Misoprostol 800 mcg daily (given as two or four divided doses)
Number of subjects: 2900

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 2900

Group type: COMPARATOR
Intervention: Cimetidine (conventional doses)
Number of subjects: 2900
Study: 31273763

Group type: EXPERIMENTAL
Intervention: SMS-ICU
Number of subjects: 3282

Group type: EXPERIMENTAL
Intervention: SAPS II
Number of subjects: 3282

Group type: EXPERIMENTAL
Intervention: SOFA score
Number of subjects: 3282
Study: 27318406

Group type: EXPERIMENTAL
Intervention: Stentless Group (porcine Freestyle® Medtronic bioprosthesis)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Stented Group (porcine Mosaïc® Medtronic bioprosthesis)
Number of subjects: 62
Study: 26001508

Group type: EXPERIMENTAL
Intervention: F‐EAM system
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional EAM system
Number of subjects: 80
Study: 23136002

Group type: EXPERIMENTAL
Intervention: 30 ng desmopressin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 60 ng desmopressin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 125 ng desmopressin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 250 ng desmopressin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 500 ng desmopressin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 20214847

Group type: EXPERIMENTAL
Intervention: Anti-psychotic medications
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Prior outpatient mental health use
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Non-Hispanic white race
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Higher ADCS-ADL scores
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Lower utility scores on HUI-III
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Worse cognition on Mini-mental State Examination
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Lower scores on ADCS-ADL
Number of subjects: 418
Study: 19501212

Group type: EXPERIMENTAL
Intervention: EE/CMA (ethinyl estradiol 0.03 mg and chlormadinone acetate 2 mg)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study: 16877180

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (CBI)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 231
Study: 12668792

Group type: EXPERIMENTAL
Intervention: Salbutamol (15 micro g/kg over 20 minutes)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Aminophylline (5 mg/kg over 20 minutes)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 44

Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 44
Study: 10872310

Group type: EXPERIMENTAL
Intervention: Heating routine before exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control method (not specified)
Number of subjects: 30
Study: 8826495

Group type: EXPERIMENTAL
Intervention: Demographic variables (education level, marital status)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Age and gender interaction
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Duration of pain
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Work status and litigation status interaction
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Comprehensive analysis of work status, education level, and marital status
Number of subjects: 254
Study: 1592345

Group type: EXPERIMENTAL
Intervention: Epinephrine (n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Norepinephrine (n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epoprostenol added to Epinephrine (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epoprostenol added to Norepinephrine (n = 10)
Number of subjects: 30
Study: 6146875

Group type: EXPERIMENTAL
Intervention: Booklet on breast self-examination
Number of subjects: 28788

Group type: COMPARATOR
Intervention: Control group (no booklet)
Number of subjects: 28788
Study: 30649227

Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg BID
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 30382903

Group type: EXPERIMENTAL
Intervention: Laser hair depilation of the sacrococcygeal region
Number of subjects: 272

Group type: COMPARATOR
Intervention: Best recommended standard of care
Number of subjects: 272
Study: 25979609

Group type: EXPERIMENTAL
Intervention: Intranasal vasopressin (AVP) 20 IU
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) 24 IU
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 22902348

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg orally once daily starting on cycle day 8 until follicle rupture or onset of next menses)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg orally once daily starting with LH surge for 6 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control cycle (no treatment)
Number of subjects: 20
Study: 21200344

Group type: EXPERIMENTAL
Intervention: Walking slower uphill at 0.75 m·s on a 6° incline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Walking slower uphill
Number of subjects: 12

Group type: COMPARATOR
Intervention: Brisk level walking
Number of subjects: 12
Study: 19281728

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg tablet (test formulation)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg tablet (reference formulation)
Number of subjects: 64
Study: 17309456

Group type: COMPARATOR
Intervention: Ketoconazole 2% cream
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metronidazole 0.75% gel
Number of subjects: 60
Study: 15679233

Group type: EXPERIMENTAL
Intervention: Pristinamycin 1 g bid for 4 days
Number of subjects: 485

Group type: COMPARATOR
Intervention: Cefuroxime axetil 250 mg bid for 5 days
Number of subjects: 485
Study: 11329468

Group type: EXPERIMENTAL
Intervention: Standardized assay using rabbit complement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Goldschneider assay using human complement
Number of subjects: 0
Study: 8203786

Group type: EXPERIMENTAL
Intervention: Daflon 500 mg
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 183
Study: 3109088

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) starting one week prior to transplant
Number of subjects: 137

Group type: COMPARATOR
Intervention: Hydration with a 5% dextrose solution containing electrolytes, minerals, trace elements, and vitamins (Control)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 137
Study: 28891743

Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - 12 weeks of cardiorespiratory and strength exercises
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control Group (CG) - Treatment as usual
Number of subjects: 28
Study: 28177705

Group type: EXPERIMENTAL
Intervention: Peppermint essential oil (PEP)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control
Number of subjects: 7
Study: 26665571

Group type: EXPERIMENTAL
Intervention: Carbetocin 100 µg i.v.
Number of subjects: 130

Group type: COMPARATOR
Intervention: Oxytocin 10 units i.v.
Number of subjects: 130
Study: 24160333

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) plus intercourse for six cycles
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Gonadotropins plus intercourse for six cycles
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) plus IUI for six cycles
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Gonadotropins plus IUI for six cycles
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (CC only)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (gonadotropins only)
Number of subjects: 800
Study: 21167339

Group type: EXPERIMENTAL
Intervention: Emergency medical services use among women increased from 55% in Cohort 1 to 66% in Cohort 2 (P = .02)
Number of subjects: 1638

Group type: EXPERIMENTAL
Intervention: Median time from symptom onset to first medical contact: 84 minutes (men) vs 121 minutes (women) in Cohort 1; 59 minutes (men) vs 81 minutes (women) in Cohort 2 (P < .01)
Number of subjects: 1638

Group type: EXPERIMENTAL
Intervention: Median door-to-balloon time was significantly longer among women compared with men in Cohort 2.
Number of subjects: 1638

Group type: EXPERIMENTAL
Intervention: Female sex associated with a 34% (or 27-minute) increase in time from symptom onset to first medical contact.
Number of subjects: 1638

Group type: EXPERIMENTAL
Intervention: Female sex associated with a 23% (or 13-minute) increase in time from hospital arrival to reperfusion therapy.
Number of subjects: 1638
Study: 18424239

Group type: EXPERIMENTAL
Intervention: Carotid plaque screening
Number of subjects: 530

Group type: COMPARATOR
Intervention: No plaque screening (control)
Number of subjects: 530
Study: 17164991

Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 12893503

Group type: EXPERIMENTAL
Intervention: Combined therapy (16 sessions of Short Psychodynamic Supportive Psychotherapy) and pharmacotherapy (fluoxetine, amitriptyline, and moclobemide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 0
Study: 10886311

Group type: EXPERIMENTAL
Intervention: Oral high-dose methylprednisolone treatment for 15 days
Number of subjects: 50
Study: 9323143

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Neck dissection
Number of subjects: 100
Study: 8312196

Group type: EXPERIMENTAL
Intervention: Intervention cytoreduction after 3 cycles of chemotherapy
Number of subjects: 278

Group type: COMPARATOR
Intervention: 3 further cycles of chemotherapy
Number of subjects: 278
Study: 3087701

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition solution supplemented with 44.6% branched-chain amino acids (BCAA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard total parenteral nutrition (19.0% BCAA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (BCAA and control)
Number of subjects: 0
Study: 29655496

Group type: EXPERIMENTAL
Intervention: PBO long-lasting insecticidal nets
Number of subjects: 15469

Group type: COMPARATOR
Intervention: Standard long-lasting insecticidal nets
Number of subjects: 15469

Group type: EXPERIMENTAL
Intervention: Indoor residual spraying
Number of subjects: 15469

Group type: COMPARATOR
Intervention: No indoor residual spraying
Number of subjects: 15469
Study: 27977707

Group type: EXPERIMENTAL
Intervention: Inactivated trivalent influenza vaccine
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Hepatitis A
Number of subjects: 1053
Study: 25234679

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon angioplasty (PCB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 50
Study: 24131880

Group type: EXPERIMENTAL
Intervention: Psychosocial profile subgroup with higher levels of psychosocial problems
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Subgroup membership
Number of subjects: 92
Study: 20573926

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 230

Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel (chemotherapy)
Number of subjects: 230
Study: 19088832

Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor blockers
Number of subjects: 831
Study: 15766338

Group type: EXPERIMENTAL
Intervention: SoftSeal
Number of subjects: 168

Group type: COMPARATOR
Intervention: LMA Unique
Number of subjects: 168